Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer started coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a report released on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $14.00 target price on the stock.

Several other brokerages have also recently commented on CNTA. BMO Capital Markets reissued an outperform rating and issued a $15.00 price target on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Morgan Stanley increased their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an equal weight rating in a research note on Friday, June 21st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $11.00.

Centessa Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:CNTA opened at $9.43 on Thursday. The firm has a fifty day moving average of $8.98 and a two-hundred day moving average of $9.48. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $12.45. The firm has a market capitalization of $947.55 million, a P/E ratio of -6.64 and a beta of 1.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. On average, equities analysts expect that Centessa Pharmaceuticals will post -1.62 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP bought a new position in Centessa Pharmaceuticals in the 4th quarter worth $48,000. China Universal Asset Management Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 371.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after purchasing an additional 5,037 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals in the first quarter worth about $109,000. Jump Financial LLC acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $114,000. Finally, Trexquant Investment LP bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $114,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.